Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials

Background Lebrikizumab, a high-affinity monoclonal antibody targeting IL-13, previously demonstrated clinical efficacy in three randomized, double-blind, placebo-controlled Phase 3 trials that included adults and adolescents with moderate-to-severe atopic dermatitis (AD): ADvocate1, ADvocate2, and...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Adelaide A. Hebert, Carsten Flohr, H. Chih-ho Hong, Alan D. Irvine, Evangeline Pierce, Hany Elmaraghy, Sreekumar Pillai, Zach Dawson, Sherry Chen, Clara Armengol, Elaine Siegfried, Stephan Weidinger
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Taylor & Francis Group 2024-12-01
Colecção:	Journal of Dermatological Treatment
Assuntos:	Adolescents atopic dermatitis lebrikizumab efficacy quality of life
Acesso em linha:	https://www.tandfonline.com/doi/10.1080/09546634.2024.2324833
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!